Milestone Pharmaceuticals (NASDAQ:MIST) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a report released on Monday, Benzinga reports. They currently have a $25.00 price objective on the stock.

Separately, Piper Sandler lowered their price objective on Milestone Pharmaceuticals from $6.00 to $5.00 and set an overweight rating on the stock in a research note on Tuesday, March 5th.

Milestone Pharmaceuticals Stock Up 1.5 %

Shares of MIST opened at $1.34 on Monday. The company has a market capitalization of $71.37 million, a PE ratio of -1.07 and a beta of 1.63. Milestone Pharmaceuticals has a 12 month low of $1.22 and a 12 month high of $3.86. The stock’s 50-day moving average price is $1.56 and its two-hundred day moving average price is $1.68. The company has a current ratio of 22.75, a quick ratio of 22.75 and a debt-to-equity ratio of 1.27.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.05. On average, analysts anticipate that Milestone Pharmaceuticals will post -0.79 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Milestone Pharmaceuticals stock. BNP Paribas Financial Markets lifted its holdings in shares of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) by 177.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,900 shares of the company’s stock after purchasing an additional 10,800 shares during the quarter. BNP Paribas Financial Markets’ holdings in Milestone Pharmaceuticals were worth $30,000 at the end of the most recent quarter. 86.18% of the stock is owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.